J&J in deal to develop microbiome drug for bowel diseases

(Reuters) - Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders, such as Crohn's disease and ulcerative colitis.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news